. 2004 Feb;135(2):273–279. doi: 10.1111/j.1365-2249.2004.02367.x

Table 2.

Biochemical and metabolic determinations

	Patients with LD

Characteristics	LD-FA (n = 12)	LD-LA (n = 15)	no LD (n = 15)	Healthy controls (n = 12)
Cholesterol(mmol/l)	6·3 (5·2–7·0)	6·0 (5·3–7·1)	5·9 (4·7–6·6)	5·8 (4·5–6·5)
HDL (mmol/l)	1·0 (0·9–1·1)	1·1 (0·9–1·3)	1·2 (1·0–1·5)	1·3 (1·15–1·65)^††
LDL (mmol/l)	4·3 (3·3–4·9)	4·0 (3·1–5·0)	3·9 (2·9–4·9)	3·7 (3·0–4·6)
Triglycerides(mmol/l)	2·5 (1·9–3·5)	2·5 (2·3–3·5)	2·5 (1·3–2·5)^*	1·1 (0·7–2·4)^†††
Glucose (mmol/l)	5·0 (4·7–5·4)	4·9 (4·7–5·3)	5·0 (4·8–5·5)	4·8 (4·6–5·0)
Insulin (ρmol/l)	97·5 (64·5–110·5)	55·0 (38·0–90·0)	55·0 (43·5–74·0)	34·5 (20·0–94·0)^‡‡
IR-HOMA	3·74 (2·15–4·58)	2·0 (1·55–3·6)	2·02 (1·67–2·84)	1·12 (0·71–3·36)^‡‡

Results expressed are median and 25% and 75% quartiles; LD, lipodystrophy; LD-FA, HIV-infected patients with lipodystrophy with fat accumulation; LD-LA, HIV-infected patients with lipodystrophy without fat accumulation; no-LD, HIV-infected patients without lipodystrophy; Controls IR-HOMA, insulin resistance as measured by homeostasis mode of assessment [39]; LDL, low density lipoprotein; HDL, high density lipoprotein. (controls). LD-FA and LD-LA did not differ with regards to the lipid profile.

denotes significant difference (*P < 0·05) between LD-FA/LD-LA and no-LD;

^†

denotes significant difference († = P < 0·05;

^††

denotes significant difference = P < 0·01,

^†††

denotes significant difference = P < 0·001) between LD-FA/LD-LA and controls;

^‡

denotes significant difference (

^‡‡

denotes significant difference = P < 0·01) between LD-FA and controls.